search

Active clinical trials for "Mycosis Fungoides"

Results 101-110 of 218

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation...

Mycosis Fungoides

To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or AP ointment who did not achieve a complete response.

Completed2 enrollment criteria

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic...

Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH1140 more

This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.

Completed39 enrollment criteria

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor,...

Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell Lymphoma63 more

This phase I trial is studying the side effects and best dose of bevacizumab and cediranib maleate in treating patients with metastatic or unresectable solid tumor, lymphoma, intracranial glioblastoma, gliosarcoma or anaplastic astrocytoma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Cediranib maleate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bevacizumab and cediranib maleate may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving bevacizumab together with cediranib maleate may kill more cancer cells.

Completed35 enrollment criteria

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Adult Grade III Lymphomatoid GranulomatosisAnaplastic Large Cell Lymphoma60 more

This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas. PXD101 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PXD101 may also cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving PXD101 together with bortezomib may kill more cancer cells.

Completed42 enrollment criteria

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma,...

Cutaneous T Cell LymphomaMycosis Fungoides

The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.

Completed34 enrollment criteria

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

LymphomaT-Cell2 more

The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).

Completed14 enrollment criteria

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma49 more

This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with metastatic or unresectable solid tumors or lymphomas. Drugs used in chemotherapy, such as 17-DMAG, work in different ways to stop cancer cells from dividing so they stop growing or die

Completed45 enrollment criteria

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed...

Acute Undifferentiated LeukemiaAdult Nasal Type Extranodal NK/T-cell Lymphoma63 more

This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion in treating patients with hematopoietic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate, and total body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also keep the patient's immune response from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

Completed36 enrollment criteria

Interleukin-2 in Treating Patients With Mycosis Fungoides

Lymphoma

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides.

Completed72 enrollment criteria

Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides

Refractory Mycosis Fungoides

This pilot phase II trial studies how well photodynamic therapy works in treating patients with mycosis fungoides that does not respond to treatment. Photodynamic therapy uses a drug, such as aminolevulinic acid hydrochloride, that becomes active when it is exposed to light. The activated drug may kill cancer cells.

Completed25 enrollment criteria
1...101112...22

Need Help? Contact our team!


We'll reach out to this number within 24 hrs